Dr. Reddy's Laboratories
Indian generic drugmaker copying off-patent medicines like lenalidomide and semaglutide for US and global markets.
On the record
Checkpoint: Target commercial resupply of generic semaglutide after API remediation
The call
Dr. Reddy's faces a lenalidomide cliff, a stalled semaglutide launch, and a looming US tariff, with rivals already moving faster on the same drugs.
Dr. Reddy's makes and sells generic medicines and branded drugs, mostly from India, to hospitals and pharmacies around the world. The company is hard to put out of business because Indian drug makers have built factories and regulatory approvals over decades that new competitors cannot quickly copy, but Dr. Reddy's does not have any real advantage over rivals like Apotex, Sandoz, or other Indian drug makers who have the same factories and approvals. Three urgent problems are hitting at once: a major weight-loss drug ingredient it makes is selling much less because the patent protection expires soon, a contamination issue in its production of another weight-loss ingredient is slowing sales, and US tariffs on Indian drugs could rise to 200 percent by 2029 on its biggest revenue source. The one thing that could change everything is whether Dr. Reddy's can fix the contamination problem and restart full supplies by late 2026; if it cannot, faster rivals will grab its market share and the company's growth will stop for two years.
Why
01
AI pressure: None apparent. No AI lab makes generic pills; AI mostly helps Dr. Reddy's speed up formulation work and quality control internally. Could AI do the core job? Unlikely.
02
Bigger players: Apotex, Sandoz, Cipla, Sun Pharma, Aurobindo. Apotex already ships generic semaglutide in Canada while a Dr. Reddy's API failure pushes its own launch to Nov 2026 at best. Could a giant copy it? Probably.
03
What protects it. FDA-grade manufacturing and regulatory approvals across 50+ markets that most companies cannot replicate quickly, even if rivals share the same edge.
What would change this call
Semaglutide commercial resupply either ships by Nov 2026 or slips past Q1 CY2027. Shows whether Apotex/Sandoz lock in first-mover generic-GLP-1 share permanently.
FDA decision on abatacept biosimilar due Dec 2026, given June 2026 Form 483 at Bachupally plant. Tests whether manufacturing quality issues cost Dr. Reddy's a pipeline approval to rivals.
North America lenalidomide revenue trend in Q2 and Q3 FY27 results. Confirms whether the -35% cliff keeps deepening as peer generics take pricing share.
FDA decision on abatacept biosimilar due Dec 2026, given June 2026 Form 483 at Bachupally plant. Tests whether manufacturing quality issues cost Dr. Reddy's a pipeline approval to rivals.
North America lenalidomide revenue trend in Q2 and Q3 FY27 results. Confirms whether the -35% cliff keeps deepening as peer generics take pricing share.
Key numbers
- North America revenue down 35% YoY on lenalidomide cliff
- Q1 FY27 net profit fell 69% YoY to Rs443.5 crore
- Targeting ~12 million generic semaglutide pens in FY27
Named risks
- Semaglutide resupply slips past November 2026 target, ceding GLP-1 lead to rivals.
- Lenalidomide exclusivity cliff continues eroding North America revenue through FY27.
- US tariffs on imported generics escalate to 100% by 2028 and 200% by 2029.
- Form 483 observations at Bachupally facility jeopardize abatacept biosimilar approval.
- Recurring quality failures like the 2026 API impurity undermine first-mover advantage.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Apotex | gaining on | Launched generic semaglutide in Canada during Dr. Reddy's supply halt, July 2026 |
| Novo Nordisk, Eli Lilly | contesting | GLP-1 originators whose semaglutide patent cliff Dr. Reddy's is exploiting since 2026 |
| Sandoz | gaining on | Positioned as alternative generics supplier during Dr. Reddy's Nov 2026 resupply gap |
| Sun Pharma, Cipla, Lupin, Aurobindo | contesting | Comparable or larger US revenue exposure amid same 2026 tariff threat |
Questions people ask
- Is Dr. Reddy's Laboratories profitable in 2026?
- Yes but declining sharply. Q1 FY27 (quarter ended June 30, 2026) net profit fell 69% year-over-year to about ₹443.5 crore, while revenue dropped roughly 6% to ₹8,070.5 crore, driven by lost lenalidomide sales and a ₹240 crore semaglutide provision.
- Why is Dr. Reddy's stock falling in 2026?
- Dr. Reddy's shares were down about 19% year-to-date as of July 22, 2026, near 52-week lows, after a lenalidomide exclusivity cliff cut North America revenue 35% YoY, a semaglutide API impurity halted supply, and a proposed US generics tariff spooked investors.
- Could AI replace Dr. Reddy's Laboratories?
- No. Its revenue comes from regulated generic and biosimilar manufacturing requiring FDA/GMP approvals AI cannot obtain. AI is used only as an internal tool, such as Aurigene's Aurigene.AI drug-discovery platform, which the company says cut discovery cycle time by 35% as of April 2024.
- Who is Dr. Reddy's biggest rival in the GLP-1 generics race?
- Apotex. It launched generic semaglutide in Canada during July 2026 while Dr. Reddy's had halted its own commercial semaglutide supply after an out-of-specification API impurity was found during scale-up, letting Apotex claim first-mover advantage in that market.
- Who owns Dr. Reddy's Laboratories?
- It is publicly traded with no parent company, listed on NSE, BSE and NYSE (RDY), part of the NIFTY 50. The Reddy family remains influential through leadership roles held by Co-Chairman Satish Reddy and Co-Chairman/MD G.V. Prasad, reappointed for 2026-2031.
- When will Dr. Reddy's semaglutide supply resume after the API problem?
- The company targets resuming commercial semaglutide supply by November 2026, aiming for 6 to 7 million pens between November 2026 and March 2027, but as of July 23, 2026 management cited only 80 to 90 percent confidence in hitting that date.
Timeline
- 2026-07-23Trump announces phased US generic drug tariff, 0% then 100% by 2028 then 200% by 2029
- 2026-07-22Q1 FY27 results: revenue down 6% YoY, net profit down 69% YoY to ~443.5 crore
- 2026-07-09Semaglutide commercial supply halted after API impurity found during scale-up
- 2026-06-30FDA pre-license inspection at Bachupally facility yields Form 483 with 7 observations
- 2026-05-15Generic semaglutide injection launched in Canada
- 2026-04-28Health Canada approves generic semaglutide injection
- 2025-12-31Abatacept IV biosimilar BLA accepted by US FDA
- 2025-09-11Announces $50.5 million acquisition of Janssen's STUGERON brand portfolio
- 2024-04-03Aurigene launches Aurigene.AI drug discovery platform, company claims 35% faster cycle time
Revision history
24 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Dr. Reddy's Laboratories Ltd. Company Profile & Executives - WSJ (2026-01-08)
- Dr. Reddy's Laboratories (2026-07-15)
- gurufocus.com (2026-07-23)
- Dr Reddy's to Enter Anti-Vertigo Market with $50.5 Million Acquisition (2025-09-11)
- Dr. Reddy's Laboratories Ltd (RDY) Earnings Dates, Call Summary & Reports (2026-06-01)
- Dr. Reddy's Q1FY26 Financial Results (2025-07-23)
- Dr. Reddy's Q3 & 9MFY26 Financial Results (2026-01-21)
- Dr Reddy's Q1 profit falls 69% (2026-07-22)
- Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down (2026-07-23)
- Q4 and FY26 Earnings Conference Call Transcript (2026-05-12)
- Dr Reddy's delays semaglutide supplies due to API issue (2026-07-09)
- Dr Reddy's aims to resume semaglutide supply by November after API fix (2026-07-23)